What moved 1672.HK stock pre-market today?

1672.HK stock jumped after Ascletis announced U.S. FDA IND clearance for ASC30, a Phase II diabetes study, which acts as a near-term clinical catalyst for the share price.

What are Meyka AI's price targets for 1672.HK stock?

Meyka AI's forecast model projects **HK$13.02** monthly, **HK$16.80** quarterly, and **HK$25.02** at 12 months, with implied upsides of **5.60%**, **36.25%**, and **102.92%** respectively from HK$12.33.

Should I buy 1672.HK stock after the IND clearance?

The IND clearance is a positive catalyst, but 1672.HK stock carries biotech execution risk and negative EPS; consider position size, trial milestones and sector volatility before buying.

Where can I find the official news on the ASC30 IND for 1672.HK stock?

The company issued the IND announcement via its press release and major outlets; see the stock quote and news feed on Yahoo Finance for the full release and updates.

HK Stocks

Ascletis (1672.HK) +7.03% pre-market Jan 2026: FDA IND clearance signals upside

ByHuzaifa Zahoor January 6, 2026January 6, 2026

The trading session opens with Ascletis Pharma Inc. (1672.HK) up 7.03% in pre-market trade on Jan 2026 after U.S. FDA IND clearance for ASC30 was announced. 1672.HK stock is trading at HK$12.33, with volume near 3,026,000 shares and a market cap of about HK$11.88B on the HKSE in Hong Kong. We view the IND clearance as the immediate catalyst behind the move and outline why this matters for valuation, technicals, and near-term outlook. Meyka AI’s real-time analysis flags catalysts and model forecasts for investors to consider.